Request Appointment
520 E 70th St# STARR3New York, NY 10021
Overview of Dr. Yamshon
Dr. Samuel Yamshon is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and New York-Presbyterian Hospital. He received his medical degree from University of California, Davis, School of Medicine and has been in practice 0 years. He is one of 372 doctors at New York-Presbyterian Hospital and one of 372 doctors at New York-Presbyterian Hospital who specialize in Oncology. He has more than 20 publications and over 150 citings.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2016 - 2019
University of California, Davis, School of MedicineClass of 2016
Certifications & Licensure
NY State Medical License 2019 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study.Samuel Yamshon, Jean L Koff, Melissa C Larson, Brad S Kahl, Carla Casulo
American Journal of Hematology. 2025-04-01 - Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study.Mohamed A Kharfan-Dabaja, Razan Mohty, Neela Easwar, Patrick Johnston, Madiha Iqbal
Bone Marrow Transplantation. 2025-03-01 - 4 citationsEZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function.Yusuke Isshiki, Xi Chen, Matt Teater, Ioannis Karagiannidis, Henna Nam
Cancer Cell. 2025-01-13
Abstracts/Posters
- Markers of Lenalidomide and Rituximab Treatment in Indolent Non-Hodgkins LymphomaYamshon S, Qi L, et al., UC Davis Research Symposium, UC Davis, 4/2014
- Correlative Analysis and Clinical Update Of a Phase II Study Using Lenalidomide and Rituximab In Patients With Indolent Non-Hodgkin Lymphoma.Yamshon S, Qi L, Yu C, et al., Blood, 12/2013
Lectures
- Non-Destructive Post-Transplant Lymphoproliferative Disorder Shows Distinct Clinical Features with HHV-6 Reactivation in a Subset61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Bioethics and Transgender HealthUniversity of Pennsylvania - 10/2014
- Ethical Decision-MakingHarvard University - 10/2014
- Join now to see all
Press Mentions
- The Battle for Frontline Therapy on MCL: Lenalidomide plus RituximabMarch 2nd, 2021
Mantle Cell Lymphoma: Long-Extending Remissions with Lenalidomide, RituximabDecember 16th, 2020
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
